BrainChild Bio raises $116M Series A to fund Phase 2 CAR‑T trial for pediatric diffuse intrinsic pontine glioma
BrainChild Bio raised $116 million in Series A financing to advance CAR-T therapies into the central nervous system, funding a Phase 2 trial of its lead candidate for pediatric diffuse intrinsic pontine glioma while planning future adult indications.
BMore: FinSMEs, Endpoints News, BioSpace, Fierce Biotech, GEN - Genetic Engineering and Biotechnology News
- FinSMEs: BrainChild Bio Raises $116M Series A to Fund Phase 2 ILLUMINATE Trial of BCB‑276 for DIPG
-
Endpoints News / Kyle LaHucik: BrainChild Bio raises $116M Series A to fund pivotal B7-H3 CAR-T trial for pediatric DIPG
- Also at: BioSpace, Fierce Biotech, GEN - Genetic Engineering and Biotechnology News
No comments yet.